---
title: "Novo Nordisk Predicts 2026 Revenue Drop From Price Cuts and Competition"
summary: "Novo Nordisk, the Danish company that makes the weight‑loss drugs Wegovy and Ozempic, says it will see a 5‑13 % drop in 2026 sales. The fall comes after the U.S. government, led by former President Trump, pushed for lower prices, plus patent expiries that open the door to cheaper generics. The company’s shares slid 17 %, wiping out gains. Its new oral Wegovy pill has taken off, but price pressure is still intense."
section: "Business"
category: "Medical Research News"
imageUrl: "https://media.guim.co.uk/7ac746697084654dc107382432881b9fe69e8642/4_0_4354_3483/500.jpg"
publishedAt: "2026-02-04T10:51:40Z"
guardianId: "business/2026/feb/04/wegovy-ozempic-forecast-revenue-share-price-drop"
---

Novo Nordisk, the Danish company that makes the weight‑loss drugs Wegovy and Ozempic, says it will see a 5‑13 % drop in 2026 sales. The fall comes after the U.S. government, led by former President Trump, pushed for lower prices, plus patent expiries that open the door to cheaper generics. The company’s shares slid 17 %, wiping out gains. Its new oral Wegovy pill has taken off, but price pressure is still intense.
